NSAIDS    body {font-family: 'Open Sans', sans-serif;}

### NSAIDS

Cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) Inhibitors  
**Inhibiting COX-1:** may inhibit Thromboxane A-2 and cause gastrointestinal bleeding and ulcers.  
**Inhibiting COX-2:** leads to the anti-inflammatory, analgesic and antipyretic effects.  
Most NSAIDS inhibit both COX-1 and COX-2.  
**  
NSAIDS and Neuraxial or Deep Regional Block**

table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Minimal Time between  
last dose and block | Can it be given with  
epidural catheter in place? | Minimal time restarting  
aspirin after neuraxial block |
| --- | --- | --- |
| No restrictions when  
NSAIDS is not concurrent  
with other anticoagulants | No restrictions when  
NSAIDS not concurrent  
with other anticoagulants | No restrictions when  
NSAIDS not concurrent  
with other anticoagulants. |

  
**Change in aPTT or INR:** No  
**Peak effect:** hours**Time for normal hemostasis after discontinuation:** 1-3 days  
  
The clinical effects of NSAIDs depend largely on their selectivity for these enzymes.  

Barash, Stoelting, Cullen, Calahan, Stock, Ortega and Sharar; Clinical Anesthesia Fundamentals ; 2015  
  
Patrono C, Patrignani P, García Rodríguez LA.  
**Cyclooxygenase-selective inhibition of prostanoid formation** : transducing biochemical selectivity into clinical read-outs. _J. Clin. Invest._ 108(1), 7–13 (2001).  
  
Knights, Kathleen. **"Defining the COX Inhibitor Selectivity of NSAIDs: Implications for Understanding Toxicity."** Web MD LLC. Retrieved 17 February 2013.  
  
Anticoagulation 3rd Edition  
_Regional Anesthesia and Pain Medicine_ :  
January/February 2010 - Volume 35 - Issue 1 - pp 64-101  
doi: 10.1097/AAP.0b013e3181c15c70  
Asra Practice Advisory  
  
British Journal of Anaesthesia 111 (S1): i96–i113 (2013) doi:10.1093/bja/aet401  
http://bja.oxfordjournals.org/content/111/suppl\_1/i96.full.pdf+html  
  
Regional anaesthesia in the patient receiving antithrombotic and antiplatelet therapy  
http://bja.oxfordjournals.org/content/107/suppl\_1/i96.full#ref-4  
T.T. Horlocker  
Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905, USA  
  
Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003;28:172-97  
  
Clinical Anesthesia Fundamentals; 2015  
Barash, Cullen, Stoelting, Cahalan, Stock, Ortega and Sharar  
  
Rheumatology (Oxford) (2002) 41 (4): 458-461.  
**Platelet function is inhibited by non** **‐** **selective non** **‐** **steroidal anti** **‐** **inflammatory drugs but not by cyclo** **‐** **oxygenase** **‐** **2** **‐** **selective inhibitors in patients with rheumatoid arthritis  
**E. A. J. Knijff‐Dutmer; E. M. Kalsbeek‐Batenburg; J. Koerts and M. A. F. J. van de Laar  
  
Major Side Effects of NSAIDS & COX-2 Selective Inhibitors  
Tulane School of Medicine  
http://tmedweb.tulane.edu/pharmwiki/doku.php/nsaid\_side\_effects  
  
Acta Biol Med Ger. 1978;37(5-6):715-23.  
A possible role of thromboxane A2 (TXA2) and prostacyclin (PGI2) in circulation.Gryglewski RJ, Dembínska-Kieć A, Korbut R.  
https://www.ncbi.nlm.nih.gov/pubmed/369254